App-Quantinova.ai

CHARACTERISTICS OF PATIENTS WITH CANCER TREATED FOR VENOUS THROMBOEMBOLISM IN GENERAL HOSPITAL DR. JOSIP BENČEVIĆ DURING FIVE YEARS

Hrvoje Holik - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

PHASE II RANDOMIZED CLINICAL TRIAL COMPARING ROPEGINTERFERON VERSUS PHLEBOTOMY IN LOW-RISK PATIENTS WITH POLYCYTHEMIA VERA. RESULTS OF THE PRE-PLANNED INTERIM ANALYSIS

Tiziano Barbui - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

VTE-BLEED SCORE TO PREDICT BLEEDING COMPLICACTIONS IN PATIENS WITH VENOUS THROMBOEMBOLISM: FROM THE RIETE REGISTRY

Marta Hidalgo Soto - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

UNDERLYING CANCER IN PATIENTS WITH ARTERIAL THROMBOEMBOLISM

Avi Leader - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

INCREASED RISK OF VENOUS AND ARTERIAL THROMBOSIS IN ALK-REARRANGED LUNG CANCER

Hanny Al-Samkari - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

IMPACT OF COLD AGGLUTININ DISEASE REAL-WORLD TREATMENTS ON THROMBOSIS AND MORTALITY—A UNITED STATES ELECTRONIC HEATH RECORD DATABASE ANALYSIS

Jun Su - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Rituximab

THROMBOSIS IN ACUTE MYELOID LEUKEMIA – WHO ARE THE HIGH RISK PATIENTS?

Mirjana Mitrovic - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

GENETIC VARIANTS OF HEMOPHILIA B IN VALENCIAN COMMUNITY (SPAIN): DETECTION BY MEANS OF A NGS GENE PANEL.

Angel Zuniga - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

IMPACT OF INTRAVASCULAR HEMOLYSIS AND MULTITREATMENT ON THROMBOSIS OCCURRENCE IN AUTOIMMUNE HEMOLYTIC ANEMIA

Bruno Fattizzo - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES TO IDENTIFY POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME

Martina Barone - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Hydroxyurea

CLINICAL SIGNIFICANCE OF MPL MUTATIONS IN ESSENTIAL THROMBOCYTEMIA PATIENTS: RISK ASSESMENT OF MYELOFIBROTIC TRANSFORMATION.

Roco Garca-Serra - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE: CLINICOPATHOLOGICAL CHARACTERISATION AND OUTCOME ANALYSIS

Paul Deschamps - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

KIDNEY DYSFUNCTION IS ASSOCIATED WITH INCREASED THROMBOSIS BUT NOT SEVERE BLEEDING EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: AN ANALYSIS FROM THE GERMAN GSG-MPN BIOREGISTRY

Judith Gecht - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

MYSEC-PROGNOSTIC MODEL AND PREVIOUS THROMBOTIC EVENTS PREDICT THE RISK OF THROMBOSIS IN POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY OF THE MYSEC GROUP

Barbara Mora - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

OUTCOMES OF 99 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (SVT): FIRST REPORT FROM THE UK MASCOT REGISTRY

Yanrong Jiang - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Venous thrombosis

N/A

SIGNIFICANCE OF ANTINUCLEAR ANTIBODIES IN PRIMARY IMMUNE THROMBOCYTOPENIA. RESULTS OF THE CARMEN REGISTRY.

Guillaume Moulis - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Lercanidipine hydrochloride

PREDICTIVE FACTORS OF CARDIOTOXICITY IN LYMPHOMA PATIENTS RECEIVING ANTHRACICLINES IN THE FIRST LINE TREATMENT

Alberto Lopez-Garcia - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

PLATELET DEFICIENCY OF LONG NONCODING RNA MALAT1 PROMOTES PLATELET ACTIVITY AND THROMBUS FORMATION

Yeying Sun - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

IMPACT OF THROMBOTIC EVENTS ON SURVIVAL IN PATIENTS WITH NON-M3 ACUTE MYELOID LEUKEMIA

Giovangiacinto Paterno - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

RESULTS OF PLACENTAL HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMISTRY EXAM IN PATIENTS WITH HEREDITARY THROMBOPHILIA WITH OR WITHOUT ANTICOAGULANT TREATMENT

Janina Georgiana Goan?a - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Nitric oxide

Filters

7277 Abstracts